1. Clinical & Scientific Overview
Atropine Sulphate (Parenteral Bradycardia & OP Poisoning Antidote) (TIP-MED-000264, Reference Code [12.32]) is classified under
Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Competitive Muscarinic Acetylcholine Receptor Antagonist (Anticholinergic Antidote & Vagolytic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.32], p. 170): Atropine Inj (0.6 mg/mL), Tropine (High-Dose OP Kit 1 mg/mL or 100 mL vial) — Strengths & Dosage Forms: Injection: 0.6 mg/mL (1 mL ampoule); High-Strength OP Poisoning Vial: 1 mg/mL (30 mL / 100 mL vial); Ophthalmic Drops/Ointment: 1% w/v.
Injection: 0.6 mg/mL (1 mL ampoule); High-Strength OP Poisoning Vial: 1 mg/mL (30 mL / 100 mL vial); Ophthalmic Drops/Ointment: 1% w/v.
3. Mechanism of Action & Pharmacodynamics
Competitively blocks postganglionic muscarinic (M1–M5) receptors in bronchial smooth muscle, exocrine glands, SA/AV nodes, gut, and CNS -> reverses lethal bronchorrhoea, bronchospasm, and bradycardia (does NOT reverse nicotinic muscle paralysis—requires Pralidoxime in OP poisoning).
4. Therapeutic Indications & Evidence-Supported Uses
- First-line life-saving antidote in organophosphate (OP) and carbamate insecticide poisoning
- symptomatic sinus bradycardia / AV nodal block
- pre-anaesthetic antisialagogue
- coadministration with Neostigmine in neuromuscular reversal
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Symptomatic Bradycardia (ACLS): 0.5–1 mg IV bolus every 3–5 min (max 3 mg). Organophosphate / Carbamate Poisoning (Doubling Regimen): Start 1.8–3 mg (3–5 ampoules of 0.6 mg) IV bolus immediately; check after 5 minutes and DOUBLE the previous dose every 5 minutes (e.g., 2 mg -> 4 mg -> 8 mg -> 16 mg -> 32 mg) until 'Full Atropinisation' is achieved (clear chest with no crepitations/bronchorrhoea, HR >80 bpm, systolic BP >80 mmHg), then maintain continuous IV infusion at 10–20% of the total loading dose per hour! • Paediatric: Bradycardia: 0.02 mg/kg IV (min 0.1 mg, max single dose 0.5 mg). OP Poisoning: Start 0.05 mg/kg IV and double every 5 minutes until chest is dry.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: No absolute contraindications in life-threatening bradycardia or OP poisoning. Routine use contraindicated in narrow-angle glaucoma, myasthenia gravis (unless reversing cholinergic crisis), paralytic ileus, pyloric stenosis. • Precautions: CRITICAL INDIAN OP POISONING PEARLS: (1) The endpoint of Atropine titration in OP poisoning is a DRY CHEST (absence of bronchorrhoea/wheeze) and adequate haemodynamics—NOT pupil dilation (mydriasis lags behind or may not occur if ocular exposure occurred); (2) Correct hypoxia BEFORE or alongside the first Atropine bolus if possible to reduce ventricular fibrillation risk, but never delay Atropine in drowning-in-secretions bronchorrhoea; (3) In heart transplant recipients (denervated heart), Atropine is ineffective or causes paradoxical AV block.
Key Clinical Precautions: Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
8. Adverse Effects Profile
- Dry mouth, blurred vision, photophobia, flushing, tachycardia, urinary retention, constipation.
- Atropine toxicity/delirium ('blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone'), hyperthermia, ventricular tachyarrhythmias, acute angle-closure glaucoma.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antihistamines / TCAs / Phenothiazines -> additive anticholinergic delirium; Potassium chloride wax-matrix tablets -> GI ulceration due to delayed transit
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: For 1% Atropine eye drops: blurring of near vision and pupil dilation last for 7–14 days.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection: 0.6 mg/mL (1 mL ampoule); High-Strength OP Poisoning Vial: 1 mg/mL (30 mL / 100 mL vial); Ophthalmic Drops/Ointment: 1% w/v.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.32] (p. 170)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.36]-C179 Diphtheria Toxoid (Td) — Adsorbed Bacterial Toxoid Vaccine (Active Immunisation against Cl
- [12.36]-C180 Adsorbed Tetanus Toxoid (TT) — Adsorbed Bacterial Toxoid Vaccine (Active Immunisation against Cl
- [12.31] Naloxone Hydrochloride (Parenteral Opioid Overdose Antidote) — Pure Competitive Opioid Receptor Antagonist (Mu, Kappa & Delta An
- [12.33] Pralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator) — Cholinesterase Reactivator Oxime Antidote (Organophosphate Antido
